This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David E. Schteingart, MD; Abbas Motazedi, MD; Robert A. Noonan, PhD; Norman W. Thompson, MD

Arch Surg. 1982;117(9):1142-1146.

Abstract
• Twenty-three patients with adrenal carcinoma were treated between 1953 and 1981. Six patients underwent resection of the primary tumor and/or local radiation therapy but received no chemotherapy. Their mean survival (±SD) was 10.3±8.7 months. In contrast, 17 patients who were treated with mitotane had a mean survival of 46.6±42.7 months. Response to therapy depended on when in the course of the disease chemotherapy was instituted, and on the combination of surgical excision and drug treatment of recurrent disease. Longest survival was observed in patients who received mitotane as adjuvant therapy before clinical evidence of metastases was noted and in those who were treated with mitotane and underwent subsequent surgery for recurrent tumor. Mean survival for this group was significantly longer, 74±33 months, than for the other patients. Patients treated in this series received low-dose long-term therapy. Adverse effects of mitotane were found to be dose dependent.

(Arch Surg 1982;117:1142-1146)

Author Affiliations
From the Departments of Internal Medicine (Division of Endocrinology and Metabolism) (Drs Schteingart, Motazedi, and Noonan), and Surgery (Dr Thompson), University of Michigan Medical School, Ann Arbor. Presented at the Western Surgical Association meeting, Albuquerque, Nov 17, 1981.

Footnotes
Accepted for publication April 8, 1982.

Reprint requests to University Hospital, Room D4101 SACB, Box 02, Ann Arbor, MI 48109 (Dr Schteingart).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma
Veytsman et al.
JCO 2009;27:4619-4629.
ABSTRACT | FULL TEXT  

Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo et al.
NEJM 2007;356:2372-2380.
ABSTRACT | FULL TEXT  

Adrenocortical Carcinoma: Clinical Update
Allolio and Fassnacht
J. Clin. Endocrinol. Metab. 2006;91:2027-2037.
ABSTRACT | FULL TEXT  

Peroxisome Proliferator-Activated Receptor-{gamma} Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation
Betz et al.
J. Clin. Endocrinol. Metab. 2005;90:3886-3896.
ABSTRACT | FULL TEXT  

Long-Term (15 Years) Outcome in an Infant with Metastatic Adrenocortical Carcinoma
De Leon et al.
J. Clin. Endocrinol. Metab. 2002;87:4452-4456.
ABSTRACT | FULL TEXT  

Adrenocortical Carcinoma: Surgical Progress or Status Quo?
Kendrick et al.
Arch Surg 2001;136:543-549.
ABSTRACT | FULL TEXT  

Metastatic Congenital Adrenocortical Carcinoma: A Case Report with Tumor Remission at 31/2 Years
Godil et al.
J. Clin. Endocrinol. Metab. 2000;85:3964-3967.
ABSTRACT | FULL TEXT  

Low-Dose Monitored Mitotane Treatment Achieves the Therapeutic Range with Manageable Side Effects in Patients with Adrenocortical Cancer
Terzolo et al.
J. Clin. Endocrinol. Metab. 2000;85:2234-2238.
ABSTRACT | FULL TEXT  

Comment--Is There a Role for Low Doses of Mitotane (o,p'-DDD) as Adjuvant Therapy in Adrenocortical Carcinoma?
Barzon et al.
J. Clin. Endocrinol. Metab. 1999;84:1488-1488.
FULL TEXT  

Is There a Role for Low Doses of Mitotane (o,p'-DDD) as Adjuvant Therapy in Adrenocortical Carcinoma?
Dickstein et al.
J. Clin. Endocrinol. Metab. 1998;83:3100-3103.
ABSTRACT | FULL TEXT  

Cushing's Syndrome
Orth
NEJM 1995;332:791-803.
FULL TEXT  

Recurrent or Metastatic Disease in Select Patients With Adrenocortical Carcinoma: Aggressive Resection vs Chemotherapy
Jensen et al.
Arch Surg 1991;126:457-461.
ABSTRACT